KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Raw Materials (2017 - 2020)

Amneal Pharmaceuticals (AMRX) has 4 years of Raw Materials data on record, last reported at $162.7 million in Q1 2020.

  • For Q1 2020, Raw Materials changed N/A year-over-year to $162.7 million; the TTM value through Mar 2020 reached $162.7 million, changed N/A, while the annual FY2019 figure was $172.2 million, 5.23% down from the prior year.
  • Raw Materials reached $162.7 million in Q1 2020 per AMRX's latest filing, down from $172.2 million in the prior quarter.
  • Across five years, Raw Materials topped out at $205.1 million in Q3 2018 and bottomed at $140.1 million in Q4 2017.
  • Average Raw Materials over 4 years is $178.4 million, with a median of $180.9 million recorded in 2018.
  • Peak YoY movement for Raw Materials: increased 29.71% in 2018, then decreased 11.13% in 2019.
  • A 4-year view of Raw Materials shows it stood at $140.1 million in 2017, then rose by 29.71% to $181.7 million in 2018, then dropped by 5.23% to $172.2 million in 2019, then fell by 5.48% to $162.7 million in 2020.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $162.7 million in Q1 2020, $172.2 million in Q4 2019, and $182.8 million in Q3 2019.